Hogan Lovells advises Joh. Berenberg, Gossler & Co. KG on capital increase and placement of upsize option of Medios AG

Led by Frankfurt partner Michael Schlitt, international law firm Hogan Lovells has advised Joh. Berenberg, Gossler & Co. KG as Sole Global Coordinator in the placement of 2,616,499 new shares of Medios AG. Medios is one of the leading specialty pharma companies in Germany. The shares were placed with institutional investors by way of an accelerated bookbuilding. Bryan, Garnier & Co. acted as Lead Bookrunner and M.M.Warburg & Co (AG & Co.) KGaA as further Joint Bookrunner.

Making partial use of the Authorized Capital 2021 and excluding shareholders' subscription rights, 2,026,499 new no-par value bearer shares were placed with institutional investors at a price of €35.50 per share. Due to strong investor demand, an upsize option of 590,000 new shares from Conditional Capital 2017 was also placed in full with institutional investors. These shares were part of the Stock Option Plan 2017 for members of the Management Board and senior executives.

The new shares were admitted to trading on the Regulated Market of the Frankfurt Stock Exchange on December 7, 2021, with simultaneous admission to the sub-segment of the Regulated Market with additional admission requirements (Prime Standard). The Company will use the expected net proceeds from the capital increase to finance the cash component of its acquisition of the NewCo Pharma Group.

Hogan Lovells team for Joh. Berenberg, Gossler & Co. KG

Prof. Dr. Michael Schlitt (Partner), Mark Devlin (Counsel), Dr. Susanne Ries (Of Counsel), Dr. Timo Lockemann, Christian Schröder, Leon Lindemann (Associates), Eva-Christina Sommer (Business Lawyer) (all Corporate and Capital Markets, Frankfurt).

Joh. Berenberg, Gossler & Co. KG (In house): Dr. Martin Kniehase, Robert Zehbe

Back To Listing